Clinical Trial Goal
To find out:
- The best dose of alemtuzumab that’s safe to give before allogeneic BMT
- If allogeneic BMT and alemtuzumab is safe and works well to treat blood or immune system diseases in children, teens and young adults
You may be able to join this trial if you:
Your child:
- Has has a blood or immune system disease that's not a blood cancer. Some examples include:
- Adrenoleukodystrophy (ALD)
- Aplastic anemia
- Hurler syndrome
- Krabbe disease
- Metachromatic leukodystrophy (MLD)
- Severe combined immunodeficienty
- Sickle cell disease
- Wiskott-Aldrich syndrome
You agree to have other standard tests done to see if your child can be in the clinical trial
Trial Details
Alemtuzumab is a monoclonal antibody that targets CD52 on certain cells. Doctors think that having a certain level of alemtuzumab in the body on transplant day will help people have fewer side effects from transplant.
Before transplant, your child will get:
- Alemtuzumab – Given 1 time each day for 3 days about 2 weeks before transplant
On transplant day, the blood-forming cells from your child's donor are given to them through an IV infusion.
Your child will have blood tests to see how well the treatment is working. The clinical trial doctors will check your child's health for 100 days.
The Food and Drug Administration (FDA) has approved alemtuzumab to treat several disease. The best dose before allogeneic transplant is not known.
The Food and Drug Administration (FDA) has approved alemtuzumab to treat several disease. The best dose before allogeneic transplant is not known.
Contacts
Caitlin Cottrell, 513-803-7039, Caitlin.Cottrell@cchmc.org
Richard Cooper, richard.cooper@cchmc.org
Locations
Cincinnati Children's Hospital Medical CenterRECRUITING
Cincinnati, Ohio
Contacts:
- Caitlin Cottrell, Caitlin.cottrell@cchmc.org
- Richard Cooper, richard.cooper@cchmc.org
Sponsors
lead: Children's Hospital Medical Center, Cincinnati
